Drugs Made In America Acquisition Corp. Rights (DMAAR) Valuation Score

DMAARDrugs Made In America Acquisition Corp.

N/A

0/18

Expensive

Share Price

$0.12

15/10/2026

Book Value

(SH Equity)

N/A

Net Debt

$329.72K

Free Cash Flow

N/A

Shares Outstanding

20.40M

EPS (Diluted)

N/A

P/E Ratio

As of 15/10/2026

N/A

Mdn Growth Rate

(Net Income: 4yrs)

N/A

Dividend Yield

As of 15/10/2026

N/A

Payout Ratio

As of 15/10/2026

N/A

Sign in or register for free to view the complete valuation breakdown and historical price charts, including priced in gold chart.

🔒

Disclaimer

Capital at risk. The value of investments can go down as well as up. Past performance is not indicative of future results. This tool provides balance sheet analysis and does not constitute personal financial advice. Do your own due diligence.
The score is backward-looking — it uses trailing twelve-month (TTM) data, not forward estimates.
Sector differences are not adjusted for. Capital-intensive industries (e.g. airlines and utilities) naturally carry more debt and will score lower on debt metrics.
The score does not account for management quality, competitive moats, or macro-economic conditions.
It is designed as a screening tool, not a buy/sell recommendation. Always combine with qualitative research. The User is solely responsible for the outcome of their investments.